Thanks for posting.
Im not sure if it was the line of questioning from the anchor or something discussed prior. But a lot of the discussion was around building up Australia's biotech sector and how government can help with this. I have said for years, it's very unfortunate that many very smart Australians NEED to go to overseas capital markets to see their products/tech/research come to fruition. Outside of mining, our exports pale in comparison to the talent we have here.
Im interested to hear others thoughts, however, from recent announcements and interviews, it very much sounds like Leslie is looking to keep Imugene intact and run it well into the future. This all might really just be us getting out of 1st gear. As she puts it, 5 therapies in the clinic or close to it. Any one of them could be the most effective immunotherapies for their targets.
Others have mentioned Leslie's comments on HER-Vaxx regarding making the data look "pretty". We don't have any reason to believe the data to look much different to the interim data. And if it's similar, this is still huge compared to the incumbent Herceptin. Yes, we have a few shiny new kids on the block, however, HER-Vaxx is still groundbreaking in its own right. If PD1-Vaxx is better, then EVEN better. However, as it stands, if HER-Vaxx shows efficacy equal to Herceptin, the sum of all parts valuation, the risk-adjusted value of HER-Vaxx sits at around $1 from my numbers. It would be in the crosshairs for BP and especially Roche, as Herceptin is off-patent, bio sims eroded billions of revenue. They would jump at being able to snap up HER-Vaxx in combo with Herceptin for $5 billion ($3.9bil USD). The new combo would potentially be under a new patent (extend the life beyond current 2036 for HER-Vaxx) and they'd have the best performing therapy for HER2 cancer on the market. Much bigger market than Herceptin alone, because as we know HER-Vaxx helped those who didn't respond to Herceptin, and less resistance built up. Let's not forget also, that HER2 cancers are especially aggressive and have few effective treatment options.
Now, if PD1 performs even better than fantastic. And CF33 and CF33 CD19 etc. Within all of the therapies, we have a lot of potentially high-value assets. We really only need one of them to nail it to be valued well over a dollar, considering the market size the therapies operate in and the money being paid in the pharma space. If we get a few shots on target, and Leslie and Co playing the long game by, licensing and continuing to develop, then we could very well see an SP $2-$3+ within a few years.
I'm hoping for the long game to play out, it means the therapies will be helping thousands of very sick people all the while us being part one of the best Australian success stories. Aussie biotech cures the world of cancer?! Could you believe it?!
DYOR IMO
Expand
(20min delay)